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Noroviruses are a major cause of acute gastroenteritis worldwide and are a genetically diverse
group of viruses. Since 2002, an increasing number of norovirus outbreaks have been reported
globally, but it is not clear whether this increase has been caused by a higher awareness or
reflects the emergence of new genogroup II genotype 4 (GII.4) variants. The hypothesis that
norovirus prevalence has increased post-2002 and is related to the emergence of GII.4 is
tested in this study. Sera collected from children aged <5 years of three Dutch cross-sectional
population based cohorts in 1963, 1983 and 2006/2007 (n=143, n=130 and n=376,
respectively) were tested for specific serum IgG by protein array using antigens to GII.4 and a
range of other antigens representing norovirus GI, GII and GIV genotypes. The protein array
was validated by paired sera of norovirus infected patients and supernatants of B-cell cultures
with single epitope specificity. Evidence for norovirus infection was found to be common
among Dutch children in each cohort, but the prevalence towards different genotypes changed
over time. At the genogroup level, GI seroprevalence decreased significantly between 1963
and 2006/2007, while a significant increase of GII and, in particular, specific antibodies of the
genotype GII.4 was detected in the 2006/2007 cohort. There were no children with only GII.4
antibodies in the 1963 cohort. This study shows that the high GII.4 norovirus incidence in very
young children is a recent phenomenon. These findings are of importance for vaccine
development and trials that are currently focusing mostly on GII.4 viruses.
INTRODUCTION
Noroviruses belong to the family Caliciviridae and are a
major cause of acute gastroenteritis in outbreaks and
sporadic cases for all age groups worldwide (Ahmed et al.,
2014). Noroviruses are genetically highly diverse positive-
stranded RNA viruses that can be divided into six
genogroups (G), with a seventh genogroup that has been
recently proposed (Vinje, 2015). Viruses of GI, GII and GIV
are known to cause diarrhoeal disease in humans. The
genogroups are further divided into approximately 40
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genotypes based on their phylogenetic clustering (Kroneman
et al., 2013). The lack of a robust cell culture system for nor-
ovirus has hampered the development of serological assays
to study the impact of individual norovirus genotypes on the
population. To be able to measure the immune response to
norovirus infection, ELISA assays based on virus-like par-
ticles (VLPs) produced through expression of the viral cap-
sid protein (VP1) have been developed, but these assays
cannot distinguish exposure to different genotypes due to
high levels of cross-reactivity (Rockx et al., 2005). As a surro-
gate for virus neutralization assays, assays have been devel-
oped to measure antibodies that block the binding of
noroviruses to histo-blood group antigens (Harrington
et al., 2002). These assays eliminate cross-reactivity observed
in ELISA assays with VLPs, but are not suitable for popula-
tion studies since they are difficult to standardize, time-
consuming and need large quantities of serum and VLPs.
The VP1 consists of a conserved shell (S) domain and the
more variable P domain that contains all immunogenic sites.
Upon expression of the norovirus P domain P particles will
be formed, which are very stable and immunologically rele-
vant, but which contain less cross-reactive epitopes owing to
the absence of the conserved S-domain, as evidenced from
comparative immunization studies in mice, will be formed
(Tamminen et al., 2012; Tan et al., 2004).
Since the start of norovirus surveillance in the mid-1990s,
genogroup II genotype 4 (GII.4) has been the predominant
genotype across the globe, responsible for 62% of outbreaks
and the majority of endemic illnesses (Ahmed et al., 2014;
Siebenga et al., 2009; Verhoef et al., 2015). The norovirus
GII.4 epidemiology has similarities to that of influenza A
viruses, with new antigenic variants emerging every 2–3
years that replace the previously established variant and
herd immunity as the main evolutionary driving force
(Lindesmith et al., 2012; Siebenga et al., 2007b). Since the
mid-1990s, six GII.4 variants with pandemic spread have
been recognized: US95/96, Farmington Hills 2002, Hunter
2004, Den Haag 2006b, New Orleans 2009 and Sydney 2012
(Eden et al., 2013). Little is known about the genetic diver-
sity of the norovirus before the mid-1990s since molecular
techniques were not available then and historical faecal col-
lections are exceedingly rare. To our knowledge only one
study has looked at the GII.4 molecular epidemiology
before 1996 and has found GII.4 only in 9 of 48 (18.8%)
faecal samples collected between 1974 and 1991 (Boon
et al., 2011). Since the appearance of the GII.4 Farmington
Hills 2002 variant, an increasing number of norovirus out-
breaks have been reported compared with previous years,
but it is not clear whether this increase has been caused by a
higher awareness or is an effect of the advancement of the
emergence of antigenic drift variants of GII.4 or other evo-
lutionary effects leading to increased fitness of these viruses
at the population level (Lopman et al., 2004; Siebenga et al.,
2010). Therefore, we wanted to test the hypothesis that the
emergence of predominant GII.4 viruses have been driving
the increased norovirus burden since 2002. Sera from chil-
dren under the age of 5 years were selected from three
cross-sectional population-based serum cohorts collected in
1963, 1983 and 2006/2007 and tested with a novel multiplex
protein array to detect antibody responses to individual
norovirus genotypes. Sera of young children were chosen to
measure the impact of exposure to noroviruses in the first
years of life. The protein array was validated using poly-
clonal rabbit sera, pre- and post-sera of norovirus infected
individuals, and supernatants of B-cell cultures with single
epitope specificity.
RESULTS
Array specificity
A novel multiplex norovirus P particle protein array was
developed to help measure norovirus genotype-specific
antibodies. First, the specificity of the newly developed array
was confirmed using polyclonal sera of two rabbits immun-
ized with VP1 protein from GII.4 and GIV, respectively.
Both the GII.4 and GIV rabbit sera reacted with high signal
with the homologous antigen without significant cross-
reaction with the heterologous antigens (data not shown).
Next, we tested pre- and post-infection sera of four noro-
virus reverse transcriptase (RT-PCR) confirmed patients
infected with GII.4 Den Haag 2006b, GII.4 New Orleans
2009, GII.3 and GI.6, respectively (Table 1, Figure S1, avail-
able in the online Supplementary Material). All patients
showed a more than fourfold increase with the homologous
antigen showing that P particles in the array platform
remain intact and are recognized by norovirus antibodies in
patients. The pre-infection sera of three patients (Table 1
patients B, C and D) already showed reactivity, which was
most likely caused by previous infections as expected, since
noroviruses are one of the most common infections during
childhood. Antibody responses in the three GII infected
patients (Table 1 patients A, B and C) were exclusively
observed in the case of GII antigens, in particular, the
homologous antigen, with low levels of cross-reactivity or
boosting of previous infections with heterologous GII anti-
gens. The serum sample of the GI.6 infected patient (Table 1
patient D) showed a specific GI.6 reaction and did not bind
to the heterologous GI and GII antigens.
Quality control
Using a positive control serum, consisting of pooled human
sera, we determined that the average intra-assay coefficient
of variation (CV) for antibodies to individual P particle
antigens was 9.0% (range 6.2–13.7%) and average CV
inter-assay variation 25.7% (range 16.9–36.0%). The VLP
GIV was not included in this analysis since the human con-
trol serum was not reactive to this antigen. The potential
degradation of antibodies over time was monitored by com-
paring the magnitude of titres among cohorts. High anti-
body titres against individual antigens were observed in all
three cohorts, indicating that the serum antibodies were not
degraded (Fig. S2).
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Potential cross-reactivity of antibodies towards
the antigens on the array
Sera of children below 5 years of age (n=649) were assessed
for potential cross-reactivity patterns using the Spearman
correlation coefficient and plotting of log-transformed titres
between each possible antigen pair (Fig. 1). Antibodies
directed to antigens belonging to different genogroups typ-
ically did not show significant cross-reactivity in this age
group, with a low correlation coefficient ranging from
0.01 to 0.27. Within a genogroup, some cross-genotype
antibody reactivity was observed with correlation coeffi-
cients for heterotypic antibody reactivity ranging between
0.52 and 0.67. This pattern was not consistent among
the sera, indicating that cross-reactive patterns are complex,
reflecting large individual variability rather than a primary
technical cause.
B-cell supernatants with single epitope specificity
The observation that the sera of some of the young children
were reactive to multiple antigens raised the question
whether these children were already infected with multiple
norovirus genotypes, or their sera contained cross-reactive
antibodies, or both. Paired sera of 40 children obtained at 9
and 10 years of age were screened on the protein array for
the presence of broadly reacting serum antibody profiles.
Two donors with a broad serum profile were selected and
B-cells of these donors were polyclonally stimulated to
become antibody secreting cells (ASC). Limiting dilution
was carried out to create multiple cultures with single epi-
tope specificity. B-cell supernatants were tested on the array
to dissect the serological profiles of both donors, using lim-
iting dilution to select for single B-cell clones per well (Baas
et al., 2013; Pinna et al., 2009). Bulk cultures were first
tested and all these cultures reacted with one or multiple
antigens, confirming the serological reactivity observed in
the sera of these children. For donor 1, only 2 of 14
(14.3%) pools containing 8000 cells each were positive and
both positive clones had single genotype specificity to geno-
type GII.3 (Table 2). Donor 2 did not meet the clonal cri-
teria as 9 of 16 (56%) pools showed positive reaction to
one or multiple norovirus antigens. Some supernatants
showed broad GI reactivity, suggesting either the presence
of a broadly reactive epitope, or mixed B-cell populations.
Subsequent testing of individual supernatants’ pool 12 and
13 confirmed reactivity to multiple genotypes within GI, as
only 1 of 8 cultures harboured reactivity to norovirus anti-
gens, indicating that these reactivities were caused by a
broadly reactive epitope. However, in both donors, multiple
clones with single genotype specificity were also obtained,
with GII.3 the only reactive supernatant in donor 1, and
GI.6- and GII.4-specific supernatants in donor 2, showing
that technically, the array can measure genotype-specific
human antibodies.
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Fig. 1. Multiple scatterplot log-transformed titres of children <5 years (n=649) to determine potential cross-reactive patterns
among P particle antigens on the protein array platform. In the top right triangle Spearman correlation coefficients are plotted
between each antigen pair, with significant numbers being highlighted by enlargement.
Table 2. B-cell supernatant profiles of two donors with a broadly reacting serum profile
Symbols  , +, ++, +++ represent, respectively, a fluorescent signal of 0–500, 501–5 000, 5 001–30 000, >30 000 RFU.
Donor Cells GI.1 GI.2 GI.6 GI.8 GII.3 GII.4 GII.9
Pools 1–12 1 8000              
Pool 13 1 8000         +    
Pool 14 1 8000         +++    
Pools 1–7 2 4000              
Pool 8 2 4000           ++  
Pool 9 2 4000   +   +      
Pool 10 2 4000   +          
Pool 11 2 4000     +        
Pool 12 2 4000 +++ +++ +++ ++      
Pool 12 Culture 1–7 2 500              
Pool 12 Culture 8 2 500 +++ +++ +++ ++      
Pool 13 2 4000   +++ ++        
Pool 13 Culture 1–7 2 500              
Pool 13 Culture 8 2 500   +++ +        
Pool 14 2 4000           +++  
Pool 15 2 4000   +     ++    
Pool 16 2 4000 ++ ++ ++ ++      
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Seroprevalence
Next, the seroprevalence against different norovirus geno-
types in children <5 years (n=649) was determined. Based
on a pilot experiment with the sera of children <1 year of
age, a cut-off for positive samples was set at titre 40 (data
not shown). The overall norovirus IgG seroprevalence has
not significantly changed over time with 69.2%, 70.0% and
65.4% being seropositive for at least one genotype in 1963,
1983 and 2006/2007, respectively (Table 3, chi-squared test
for trend, P value=0.3307). In children below 1 year of age,
seroprevalence was already at a high level in 1963 and 1983
(72.0% and 70.0%, respectively), likely reflecting maternal
antibodies. In the 2006/2007 cohort the seroprevalence for
this age category was significantly lower (42.7%). More
than half of the children were already seropositive by the
second year of life, increasing to 85.3, 75.9 and 85.0% at
age 4 in 1963, 1983 and 2006/2007, respectively.
Interestingly, however, substantial differences were
observed when breaking the reactivity down to genogroups
and genotypes. At the genogroup level, GI seroprevalence
dropped over time while the prevalence of GII antibodies
increased (Fig. 2a). GIV prevalence was much higher in the
first cohort, with 30.8% in 1963 compared with 3.1% and
8.2% in 1983 and 2006/2007. Stratified by age, the highest
GI seroprevalence decrease was seen among children of age
<1 year and 2 years, while the largest GII increase was seen
among children of 1 and 3 years (Fig. 2b, c). Seroprevalence
for GIV was significantly higher in all age years in 1963
compared with cohort 1983 and 2006/2007 (Fig. 2d). All
four tested GI genotypes showed a significant reduction in
seroprevalence over time, while the increase in GII antibod-
ies was primarily caused by an increased reactivity to GII.3
and GII.4 antigens (Fig. 3a). The antigen with highest sero-
reactivity was GI.2 in 1963, GII.9 in 1983 and GII.4 in 2006/
2007.
Broadening of immune response by increasing
age
The multiplex composition of the protein array platform
enabled the simultaneous detection of norovirus antibodies
to various genotypes and allowed us to measure the age-
related broadening of the norovirus immune response
(Fig. 3b). Using a cut-off of 40, the sera were stratified into
three groups: sera without reactivity to any norovirus anti-
gen, sera with reactivity to a single antigen only and sera
with multiple reactivity. A clear age-related increase in sera
with multiple responses was observed, while the proportion
of sera with monospecific responses remained stable
(P value chi-squared test for trend among multiple, mono-
specific and non-responders, respectively: <0.0001, <0.6981
and <0.0001).
Monospecific responses
To eliminate false positives due to the presence of broadly
reactive antibodies, 157 sera from children with antibodies
limited to a single antigen were analysed separately (Table 4,
Fig. 3c). Interestingly, GII.4 antibodies were not detected as
a unique profile in the 1963 cohort, whereas they consti-
tuted 19.4% of monospecific sera in 1983 and were pre-
dominant with 58.5% in 2006/2007 indicating a dramatic
increase of antibodies to GII.4, or a closely related genotype,
over time. Furthermore, among antigens tested, GI.2 was
predominant in 1963 and GII.9 was predominant in 1983.
DISCUSSION
In this cross-sectional population study the norovirus sero-
prevalence was investigated among children <5 years of age
from whom serum was collected in 1963, 1983 or 2006/
2007. The results show that norovirus has been a common
and widespread infection among Dutch children, at least
since 1963, with no indication of an increase in the overall
seroprevalence. This confirms prior studies using ELISA or
related assays based on recombinant VLPs in China, Fin-
land, India, Japan, Korea, Spain and the UK, although quite
some variation in seroprevalence rates were observed by
geographic location and sample year, which may be due, in
part, to a lack of assay standardization (Carmona-Vicente
et al., 2015; Kobayashi et al., 2009; Menon et al., 2013;
Nurminen et al., 2011; Son et al., 2013).
Table 3. Age stratified number of sera tested and percentage of sera with reactivity to any norovirus antigen
1963 1983 2006/2007
Age group
(years)
n sera
tested
Sera norovirus
positive (%)
n sera
tested
Sera norovirus
positive (%)
n sera
tested
Sera norovirus
positive (%)
<1 25 72.0 20 70.0 110 42.7
1 to <2 32 50.0 23 56.5 57 64.9
2 to <3 25 72.0 34 67.6 74 63.5
3 to <4 27 66.7 24 79.2 75 85.3
4 to <5 34 85.3 29 75.9 60 85.0
Total 143 69.2 130 70.0 376 65.4
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It has been hypothesized that the emergence of GII.4 has
resulted in a large increase of norovirus outbreaks since
2002 (Lopman et al., 2004; Siebenga et al., 2010). Therefore,
we assessed exposure to individual norovirus genotypes
using a novel protein array. The validation experiments
showed that a person’s serological profile may contain a
mixture of genotype-specific and broadly-reactive antibod-
ies with cross genogroup reactivity, although clear discrimi-
natory serological profiles were obtained on looking at
post-infection sera. This pattern is in agreement with the
higher correlations found between antibodies and antigens
of the same genogroup compared to that with antigens
from different genogroups. Based on these observations, we
concluded that the study design allows conclusions based
on antibody trends by genogroup and genotype, although
for the latter, the potential for cross-reactive antibodies
needs to be considered when interpreting the results.
Our study shows that – despite similar overall seropreva-
lence – the exposure histories shifted drastically over the
period studied, and that the seroprevalence of GII.4 has
indeed significantly increased over the last decades, with
concomitant reduction in exposure to GI and GIV noro-
viruses. In theory, the low GII.4 seroprevalence in the 1963
and 1983 cohort could be caused by a mismatch between
circulating GII.4 variants and the antigen used in our assay
(GII.4 US95/96 antigen). This is however unlikely, as sera
from patients infected with recent GII.4 variants bound effi-
ciently to the GII.4 US95/96 variant antigen. Therefore, we
conclude that the most likely explanation for the observed
shift in norovirus exposure is that it reflects true epidemio-
logical changes. The absence of sera from the 1963 cohort
that only reacted to GII.4 suggests that either GII.4 viruses
were not circulating, or that exposure to this genotype
occurred at an older age.
Based on these data alone, we cannot draw conclusions on
the clinical impact of these shifts in exposure. All norovirus
genotypes are associated with diarrhoeal disease, but GII.4
strains are believed to be more transmissible in healthcare
settings, also cause more severe disease and are strongly
associated with the seasonal patterns in reporting (Desai
et al., 2012; Siebenga et al., 2007a). The combination of the
GII.4 variant pandemics, the association between GII.4 and
more severe symptoms, and the high GII.4 infection rates
among very young children shown in this study, could
potentially explain the increase of norovirus disease reports
since 2002. A potential bias in this study is that young chil-
dren have not yet build up an immune response against
norovirus and therefore are likely susceptible to any strain
with matching receptor specificity, while adults have already
been exposed multiple times to norovirus. Conclusions
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Fig. 2. Comparison of norovirus seroprevalence (n=649) stratified to cohort and genogroup (a). Age-related seroprevalence
(n=649) stratified to cohort for norovirus genogroup I (b), genogroup II (c) and genogroup IV (d). Error bars indicate binomial
proportion confidence intervals (Wilson score interval). Brackets above bars show significance level as determined by chi-
squared test for trend. No bracket =P>0.05, *P0.05, **P0.01, ***P0.001 and ****P 0.0001.
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based on the seroprevalence among young children can
therefore not be one-to-one translated to adults.
We also observed broadening of the antibody profile in
young children with increasing age, and reactivity to
antigens representing genotypes that are rarely found in the
Dutch national molecular surveillance. While we cannot
rule out that this broadening of antibody profile reflects
asymptomatic infections, another explanation is that these
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Fig. 3. Comparison of norovirus seroprevalence (n=649) stratified to cohort and genotype (a). Age-related broadening of the
norovirus immune response (n=649) (b). Comparison of norovirus seroprevalence in sera (n=157) with single response strati-
fied to cohort and genotype (c). Error bars indicate binomial proportion confidence intervals (Wilson score interval). Brackets
above bars show significance level as determined by chi-squared test for trend. No bracket = P>0.05, *P0.05, **P0.01,
***P0.001 and ****P0.0001.
Table 4. Genotype distribution within positive sera with single antigen response
Cohort GI.1 GI.2 GI.6 GI.8 GII.3 GII.4 GII.9 GIV.1 Total
n % n % n % n % n % n % n % n % n %
1963 2 6.3 10 31.3 5 15.6 2 6.3 1 3.1 0 0.0 4 12.5 8 25.0 32 100
1983 2 6.5 4 12.9 1 3.2 3 9.7 1 3.2 6 19.4 14 45.2 0 0.0 31 100
2006/2007 3 3.2 16 17.0 0 0.0 1 1.1 9 9.6 55 58.5 6 6.4 4 4.3 94 100
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effects are caused by high-affinity antibodies directed
against shared epitopes on the P domain of VP1, produced
by B-cells that undergo somatic hypermutation and clonal
selection upon multiple exposures to different genotypes.
Although most conserved epitopes are found on the S
domain of VP1, the B-cell supernatants in this study and
studies with mAbs have shown that the P domain contains
conserved epitopes as well (Shiota et al., 2007). An import-
ant question is whether such antibodies influence the sus-
ceptibility to subsequent infection, as has been observed
with the discovery of broadly reactive non-haemagglutina-
tion inhibition antibodies in influenza A (Wrammert et al.,
2011).
The shifting of antibody profiles for the different cohorts
shows that a GI genotype was dominant in 1963 and a GII,
other than GII.4, in 1983, which may indicate that multiple
dominant genotype switches have taken place before the
predominance of GII.4 viruses. Although the overall noro-
virus seroprevalence did not change over the years in this
study, it seems likely that genotype replacements may have
concurred with a temporary increase in outbreak activity as
is seen with GII.4 variant replacements (van Beek et al.,
2013). Further studies are warranted to measure the effect
of changes in the norovirus epidemiology on the norovirus
incidence in the population and related costs for the society.
The first norovirus vaccine candidates have been tested in
clinical trials and have been shown to curb severity of dis-
ease after a challenge with a homologous strain, which may
be helpful to reduce hospital admissions in vulnerable
patient populations and associated costs (Bernstein et al.,
2015). Field efficacy, cross-protection to drifted variants
and heterologous genotypes, efficacy in various age groups
and duration of protection needs to be evaluated in future
studies. Most importantly, however, our data suggests that
special attention needs to be paid to the potential for updat-
ing the vaccine composition following changes in the noro-
virus epidemiology. Current vaccine candidates are based
on the norovirus epidemiology associated with the domi-
nance of GII.4, but with the recent emergence of GII.17 in
Asia, the vaccine candidates may need to be updated (de
Graaf et al., 2015). Continued surveillance and a better
understanding of norovirus epidemiology is essential
knowledge for an optimal vaccine design.
METHODS
Antigens. Norovirus P particles were used as antigens since they anti-
genically resemble native virions and can be produced in Escherichia coli
expression systems at relatively low costs as described (Jiang et al., 1992;
Tan & Jiang, 2005). Furthermore, P particles only contain the highly
variable protruding (P) domain of the viral capsid protein (VP1), lack
the more conserved S domain and, therefore, contain less cross-reactive
epitopes, as evidenced by comparative immunization studies in mice
(Tamminen et al., 2012). A GIV.1 VLP produced in insect cells was
added to include antigens from all human genogroups. Since GIV is
genetically not closely related to other human genogroups we did not
expect cross-reactivity between these VLP and the P particles represent-
ing genotypes of GI and GII. We selected antigens representing common
and rare genotypes as detected by the Noronet sequence database
(Table S1, available in the online Supplementary Material) (http://www.
noronet.nl).
Norovirus protein microarrays for multiplex serology. Purified P
particles and VLPs were diluted in protein array buffer (Maine
Manufacturing) and protease inhibitor (BioVision), with final concen-
tration of 1 mg ml 1 (determined by checkerboard titration, data not
shown). Proteins were spotted in triplicate with two 333 pL spots onto
64-pad nitrocellulose-coated slides (Oncyte avid, Grace bio-labs) using a
non-contact Piezorray spotter (PerkinElmer) as described previously
(Koopmans et al., 2012). Slides were incubated with Blotto blocking
buffer (Thermo Fisher Scientific) to avoid non-specific nitrocellulose
binding, and subsequently with serial fourfold diluted human sera start-
ing at a 1 : 40 dilution. Rabbit sera and B-cell supernatants were tested at
a single dilution (1 : 20 for rabbit sera, 1 : 8 for B-cell supernatant pools
and 1 : 4 for individual cultures). After washing, slides were incubated
with goat anti-human IgG or anti-rabbit IgG (Fc-fragment specific),
conjugated with Alexa Fluor 647 fluorescent dye (Jackson Immuno
Research). Bound dye was quantified using a ScanArray Gx Plus micro-
array scanner (PerkinElmer).
Assay validation samples. Two rabbit polyclonal sera from animals
immunized with recombinant norovirus GII.4 Den Haag 2006b or GIV
VP1 protein (Immune Technology) were tested on the protein array to
confirm that antigens remain intact on the platform and to test homolo-
gous versus heterologous antigen reactivity. Pre- and post-infection sera
of RT-PCR confirmed norovirus patients were used for assay validation.
These patients were infected with GII.4 Den Haag 2006b, GII.4 New
Orleans 2009, GII.3 or GI.6, respectively (ages 5, 47, 17 and 12 years).
Use of the sera for assay validation was approved by the Erasmus MC
medical ethical committee (MEC2013-082). Further validation of the
array platform was performed by using sera (n=40, storage at  20

C)
and PBMCs (storage at  135

C) obtained from two donors (10 years)
who were sampled for a study on the memory immunity to Bordetella
pertussis (ISRCTN64117538).
Quality control. The intra- and inter-assay variation was monitored by
testing a serial diluted positive control serum consisting of pooled
human sera reacting with high norovirus titre to antigens belonging to
genogroup I and II. Samples tested on slides with a positive control devi-
ating more than one twofold dilution step from the geometric mean titre
were rejected from analysis. For the intra-assay variation, the positive
control serum was tested 16 times on a single slide and to determine the
inter-assay variation, the control serum was tested 44 times on multiple
slides within 13 weeks. The quality of the GIV VLP was tested with a
rabbit control serum (data not shown).
B-cell supernatants with single epitope specificity. B-cell super-
natants with single epitope specificity were used to test the specificity of
the protein array platform. B-cells were isolated, stimulated and cultured
in a limiting dilution assay with a slightly adjusted protocol as described
before (Baas et al., 2013). Briefly, PBMC were isolated within 24h after
venepuncture and stored at  135

C for further use. The EasySepÔ
Human CD19 positive selection kit and EasySep magnet (Stemcell Tech-
nologies) were used to isolate the B-cells from the PBMC population.
Purified B-cells were counted and re-suspended in 96-well round bot-
tom tissue culture plates with each well containing 500, 1000 or 4000
B-cells. Gamma irradiated CD40L-expressing murine ﬁbroblast L cells
were added in a concentration of 500 cells per well and 3 µg ml 1 CpG
ODN2006 (Isogen Life Sciences), 10 ng ml 1IL-2 (Miltenyi Biotec) and
10 ng ml 1 IL-10 (BD Pharmingen) was added to promote cell division
and ASC outgrowth. After 5 days of incubation at 37

C culture medium
was refreshed and cytokines were replaced by 10 ng ml 1 IL-2 and 10
ng ml 1 IL-21 (Invitrogen) to promote antibody production. Superna-
tants were harvested after 11–12 days, stored at  20

C, and in vitro IgG
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production was tested by total IgG ELISA (data not shown). Superna-
tants were subsequently tested against multiple antigens representing GI
and GII genotypes on the protein array platform.
Study samples. A total of 649 serum samples from children <5 years
of age collected in 1963, 1983 and 2006/2007 were included in the study,
with n=143, n=130 and n=376, respectively (Table 3). The sera collected
in 1963 and 1983 were obtained from a Dutch historical anonymous
collection of serum samples, which had been collected for diagnostic
purposes (not specifically for acute gastroenteritis), and stored at 20

C
since then at Erasmus MC, Rotterdam (Masurel & Mulder, 1966).
The sera collected between February 2006 and June 2007 were obtained
from a Dutch population-based cross-sectional serosurvey (van der Klis
et al., 2009). The study was approved by the Medical Ethics Committee,
Almere (ISRCTN 20164309).
Data and statistical analysis. Serum titres were computed by fitting
a four-parameter log-logistic curve to 12 luminescence readouts (four
dilutions, each antigen tested in triplicate), using the point of inflection
as titre, as described (Koopmans et al., 2012). A fixed minimum fluores-
cent signal of 3000 was chosen to reduce background reactivity and a
fluorescent signal of 65 535 was used as fixed maximum readout. Titres
below the minimum dilution were set to a value half of the reciprocal of
the minimal dilution and titres above the highest dilution were set to a
value of two times the reciprocal of the highest serum dilution. Data of
B-cell supernatants is shown as fluorescent signal (relative fluorescence
units, RFU) with the background signal subtracted since the superna-
tants were tested at a single dilution. Data analyses and statistical analysis
were performed using R version 3.0.3. The chi-squared test for trend
was performed to examine differences in seroprevalence rates between
age groups and cohorts. A P value 0.05 was considered to be signifi-
cant. The Spearman correlation coefficient was used to assess potential
cross-reactivity patterns between antibody titres detected against multi-
ple norovirus genotypes.
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